- Medical School - Case Western Reserve University (2006-2010)
- Graduate School - Case Western Reserve University (2002-2009), Molecular Virology
- Fellowship - Massachusetts General Hospital (2013-2015), Infectious Diseases
- Residency - New York Presbyterian Hospital, Cornell Campus (2010-2013), Internal Medicine
- Other Post Graduate Training - Case Western Reserve University (2002-2009)
Lenette Lu, M.D., Ph.D.
- Internal Medicine - Infectious Diseases and Geographic Medicine
Lenette Lu, M.D., Ph.D., is an Assistant Professor in the Department of Internal Medicine and the Department of Immunology at UT Southwestern Medical Center. She is an infectious disease physician-scientist.
Dr. Lu earned her medical degree and her doctoral degree in molecular virology at Case Western Reserve University School of Medicine. She completed a residency in internal medicine at New York-Presbyterian/Weill Cornell Medical Center and a clinical fellowship in infectious diseases at Massachusetts General Hospital and Brigham and Women’s Hospital. She completed a postdoctoral research fellowship at the Harvard School of Public Health and the Ragon Institute of MGH, MIT, and Harvard.
Certified by the American Board of Internal Medicine in infectious diseases and internal medicine, she joined the UT Southwestern faculty in 2019.
Dr. Lu's research focuses on how antibodies interface with the host-microbe in infectious diseases. Her studies focus on Mycobacterium tuberculosis (Mtb), the bacterium that infects one out of four people worldwide and causes tuberculosis. Her goal is to increase understanding of the immune response to infection and, ultimately, to translate observations from humans to models of disease to further inform and direct human studies that could direct diagnostic, therapeutic, and vaccine development.
Dr. Lu is a member of the American Association of Immunologists and the Infectious Diseases Society of America. In 2021, she received the American Society for Clinical Investigation’s Young Physician Scientist Award.
- American Association of Immunologists
- Infectious Diseases Society of America
- Young Physician Scientist Award 2021, American Society for Clinical Investigation
- Disease-Oriented Clinical Scholar (DOCS) Award 2019, UT Southwestern
- Maxwell Finland Award for Excellence in Research 2017, Massachusetts Infectious Diseases Society
- K08 Clinical Scientist Research Career Development Award 2017, National Institutes of Health
A Functional Role for Antibodies in Tuberculosis.
Lu LL, Chung AW, Rosebrock TR, Ghebremichael M, Yu WH, Grace PS, Schoen MK, Tafesse F, Martin C, Leung V, Mahan AE, Sips M, Kumar MP, Tedesco J, Robinson H, Tkachenko E, Draghi M, Freedberg KJ, Streeck H, Suscovich TJ, Lauffenburger DA, Restrepo BI, Day C, Fortune SM, Alter G, Cell 2016 Oct 167 2 433-443.e14
Prevention of tuberculosis in rhesus macaques by a cytomegalovirus-based vaccine.
Hansen SG, Zak DE, Xu G, Ford JC, Marshall EE, Malouli D, Gilbride RM, Hughes CM, Ventura AB, Ainslie E, Randall KT, Selseth AN, Rundstrom P, Herlache L, Lewis MS, Park H, Planer SL, Turner JM, Fischer M, Armstrong C, Zweig RC, Valvo J, Braun JM, Shankar S, Lu L, Sylwester AW, Legasse AW, Messerle M, Jarvis MA, Amon LM, Aderem A, Alter G, Laddy DJ, Stone M, Bonavia A, Evans TG, Axthelm MK, Früh K, Edlefsen PT, Picker LJ, Nature medicine 2018 02 24 2 130-143
Introduction: Physician-Scientists in the Evolving Landscape of Biomedical Research.
Lu LL, Kwon DS, Barczak AK, The Journal of infectious diseases 2018 Aug 218 suppl_1 S1-S2
Mutations in SID2, a novel gene in Saccharomyces cerevisiae, cause synthetic lethality with sic1 deletion and may cause a defect during S phase.
Jacobson MD, Muñoz CX, Knox KS, Williams BE, Lu LL, Cross FR, Vallen EA, Genetics 2001 Sep 159 1 17-33
Moving toward Tuberculosis Elimination. Critical Issues for Research in Diagnostics and Therapeutics for Tuberculosis Infection.
Keshavjee S, Amanullah F, Cattamanchi A, Chaisson R, Dobos KM, Fox GJ, Gendelman HE, Gordon R, Hesseling A, Le Van H, Kampmann B, Kana B, Khuller G, Lewinsohn DM, Lewinsohn DA, Lin PL, Lu LL, Maartens G, Owen A, Protopopova M, Rengarajan J, Rubin E, Salgame P, Schurr E, Seddon JA, Swindells S, Tobin DM, Udwadia Z, Walzl G, Srinivasan S, Rustomjee R, Nahid P, American journal of respiratory and critical care medicine 2019 Mar 199 5 564-571
Antibodies: Marking disease states in tuberculosis.
Kugelberg E, Nature reviews. Immunology 2016 10 16 11 660
Publisher Correction: IFN-γ-independent immune markers of Mycobacterium tuberculosis exposure
Lu LL, Smith MT, Yu KKQ, Luedemann C, Suscovich TJ, Grace PS, Cain A, Yu WH, McKitrick TR, Lauffenburger D, Cummings RD, Mayanja-Kizza H, Hawn TR, Boom WH, Stein CM, Fortune SM, Seshadri C, Alter G, Nature medicine 2019 Jun
BNT162b2-induced neutralizing and non-neutralizing antibody functions against SARS-CoV-2 diminish with age.
Bates TA, Lu P, Kang YJ, Schoen D, Thornton M, McBride SK, Park C, Kim D, Messer WB, Curlin ME, Tafesse FG, Lu LL, Cell reports 2022 Oct 41 4 111544
Select paramyxoviral V proteins inhibit IRF3 activation by acting as alternative substrates for inhibitor of kappaB kinase epsilon (IKKe)/TBK1.
Lu LL, Puri M, Horvath CM, Sen GC, The Journal of biological chemistry 2008 May 283 21 14269-76
To Be or Not Be a (Functional) Antibody Against TB.
Casadevall A, Cell 2016 Oct 167 2 306-307
Antibodies to Mycobacterium tuberculosis.
Casadevall A, The New England journal of medicine 2017 01 376 3 283-285
The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial.
Coler RN, Day TA, Ellis R, Piazza FM, Beckmann AM, Vergara J, Rolf T, Lu L, Alter G, Hokey D, Jayashankar L, Walker R, Snowden MA, Evans T, Ginsberg A, Reed SG, NPJ vaccines 2018 3 34
Beyond binding: antibody effector functions in infectious diseases.
Lu LL, Suscovich TJ, Fortune SM, Alter G, Nature reviews. Immunology 2018 Jan 18 1 46-61
An Inflammatory Story: Antibodies in Tuberculosis Comorbidities.
McLean MR, Lu LL, Kent SJ, Chung AW, Frontiers in immunology 2019 10 2846
IFN-γ-independent immune markers of Mycobacterium tuberculosis exposure
Lu LL, Smith MT, Yu KKQ, Luedemann C, Suscovich TJ, Grace PS, Cain A, Yu WH, McKitrick TR, Lauffenburger D, Cummings RD, Mayanja-Kizza H, Hawn TR, Boom WH, Stein CM, Fortune SM, Seshadri C, Alter G, Nature medicine 2019 06 25 6 977-987
Unique repertoire of anti-carbohydrate antibodies in individual human serum.
Luetscher RND, McKitrick TR, Gao C, Mehta AY, McQuillan AM, Kardish R, Boligan KF, Song X, Lu L, Heimburg-Molinaro J, von Gunten S, Alter G, Cummings RD, Scientific reports 2020 09 10 1 15436
Antibody Fc Glycosylation Discriminates Between Latent and Active Tuberculosis.
Lu LL, Das J, Grace PS, Fortune SM, Restrepo BI, Alter G, The Journal of infectious diseases 2020 Feb
Leveraging Antibody, B Cell and Fc Receptor Interactions to Understand Heterogeneous Immune Responses in Tuberculosis.
Carpenter SM, Lu LL, Frontiers in immunology 2022 13 830482
Engineering the supernatural: monoclonal antibodies for challenging infectious diseases.
Grace PS, Gunn BM, Lu LL, Current opinion in biotechnology 2022 Oct 78 102818
Antibody Subclass and Glycosylation Shift Following Effective TB Treatment.
Grace PS, Dolatshahi S, Lu LL, Cain A, Palmieri F, Petrone L, Fortune SM, Ottenhoff THM, Lauffenburger DA, Goletti D, Joosten SA, Alter G, Frontiers in immunology 2021 12 679973
- A Functional Role for Antibodies in Tuberculosis.
- Host microbial interactions in infectious diseases
- Antibody functions in tuberculosis
- Antibody effector functions
- Antibody glycosylation
- Humoral immunity